-
3.0T iMRI-BB sequence imaging to assess the degree of glioma removal
Time of Update: 2021-01-20
33 patients (45.2%) of the study were found to have iMRI-TFE and BB sequence enhancement imaging, and the enhanced lesions were fully cut.
, 66 (90.4%) of the 73 patients had postoperative MRI imaging showing BB and TFE sequence-enhanced lesions completely removed.
-
Sci Trans Med: New switch can regulate CAR-T cell activity
Time of Update: 2021-01-19
(Photo: www.pixabay.com) Scientists report in the journal Science Translational Medicine on the development of switchable CAR T cells that can be turned on or off by giving commonly used anti-cancer drugs.
() Source: Scientists create ON-OFF switches to control CAR T cell activity Source: M.
-
Clinical guidelines for adult diffuse gliomas
Time of Update: 2021-01-19
The guidelines focus on key treatments such as molecular and pathological diagnosis, surgery, radiotherapy, and chemotherapy, and integrate the results of clinical trials of immunotherapy and targeted therapies, and provide guidance to clinicians on the treatment of adult diffuse gliomas, including WHOII.-IV.grade adult ascytoblastomas, abrus glioblastomas and their variants, and discuss histology and molecular diagnosis and the latest treatment strategies and new therapies.
-
TIGIT Target Immunotherapy! Roche tiragolumab qualified for breakthrough drug: combined Tecentriq to treat PD-L1-positive lung cancer!
Time of Update: 2021-01-18
Jan. 07, 2021 // -- Roche recently announced that the U.S. Food and Drug Administration (FDA) has granted TIGIT target new cancer immunotherapy tiragolumab breakthrough drug qualification (BTDD) ), combined anti-PD-L1 therapy Tecentriq (Tai Sanqi, generic name: atezolizumab, atili-zhu monoanti), first-line treatment of tumors presented PD-L1 high expression, no EGFR or ALC genome tumor distortion metastasis non-small cell lung cancer (NSCLC) patients.
-
Hengrui Medicine's new adaptation to the "Apatini tablets of methulphate" has been approved: the treatment of hepatocellular carcinoma
Time of Update: 2021-01-17
a Phase III clinical (NCT02329860) study for patients who have previously received at least one line of systemic treatment (solafinie and oxalipal) failure or inability to withstand advanced hepatocellular carcinoma Compared to the placebo group, the total survival of the apatinib group was significantly extended (8.7 vs.
-
Nat Genet: A genome-wide association analysis of 100,000 plus cases identified 86 new prostate cancer susceptible mutations
Time of Update: 2021-01-17
In this study, researchers consolidated genome-wide association analysis (GWAS) data from 107,247 cases of prostate cancer and 127,006 controls (from Europe, Africa, East Asia and Spain) to identify common genetic variants associated with disease risk in populations.
-
JACC | Data on 770,000 people: An antioxidant diet does not reduce the risk of coronary heart disease!
Time of Update: 2021-01-17
, the team used two samples from the Mendel Randomization (MR) study to assess a possible causal relationship between an antioxidant diet and primary CHD risk.
, the evidence in this study does not support the protective effect of high levels of antioxidant diets on CHD risk.
-
Eur J Nucl Med Mol Imaging: the diagnostic and location value of the low PSA level recurrence metastasis after prostate cancer excision
Time of Update: 2021-01-17
155 (69.8%) had abnormal intake in 222 patients with relapsed detection rates in different PSA-level groups, suggesting a recurrence of prostate cancer.
-
Nat Commun: The gut microbiome affects the immune response around liver cancer
Time of Update: 2021-01-17
Recently, researchers published a paper in the journal Nature Communications, reporting on the use of metagenomics and metabolomic studies to characterize the gut microbiome of patients with non-alcoholic fatty liver disease (NAFLD), whether or not HCC is associated, and to assess its effects on the external immune response in in-body models.
-
East China University of Technology intends to grant 150 million yuan of DHODH inhibitor-related patents to Hainan Hai medicine
Time of Update: 2021-01-17
The transfer payment, the milestone payment and the sales commission Party A shall, in accordance with the contract, pay the patent transfer fee to Party B in milestone installments, including the total amount of RMB 150 million paid between the signing of this contract and the period during which the DHODH inhibitors obtain the drug approval number, After the DHODH inhibitor is listed, the sales credit is paid as agreed in Clause 3.4.
-
FDA approves first complementary therapy for non-small cell lung cancer with 80% reduction in disease recurrence
Time of Update: 2021-01-17
Fda approves Tagrisso (osimertinib, Osimtinib), a third-generation EGFR inhibitor developed by AstraZeneta, as the first complementary therapy to treat patients with non-small cell lung cancer (NSCLC) with specific types of gene mutations in tumors.
-
Eur Radiol: In the MRI image, the human eye can not find the hepatoblast cell carcinoma immunotype, texture analysis can be found!
Time of Update: 2021-01-17
Texture analysis features a strated map of the risk of ICC patients predicting total lifetime.
Representative cases: Inflammatory and non-inflammatory ICC results show that MRI texture characteristics in ICC patients can be used as predictive IP and OS biomarkers.
-
FDA grants Zenotuzumab 'fast track qualification' to treat NRG1 gene fusion tumors
Time of Update: 2021-01-16
Merus is currently recruiting patients for Phase I/II clinical trials aimed at evaluating the effectiveness of Zenocutuzumab's single-drug treatment of pancreatic cancer and other solid tumors that are fusion of the NRG1 gene.
-
Hypertention: The "revenge" of cancer and high blood pressure
Time of Update: 2021-01-16
hypertension caused by anti-cancer treatment is the most common complication (38%) in cancer patients, and a higher proportion of patients with high blood pressure, older age, and higher body mass index.
-
ESMO Open: Incidence of pathogenic BRCA1/2 embryoline mutations in pancreatic cancer patients
Time of Update: 2021-01-16
pancreatic cancer patients of any age, gBRCApv screening at the Italian Oncology Centre within 3 months of diagnosis, with no choice.
patients with a family history of vs non-potential BRCA-related tumors had mutation rates of 14% vs 6%, respectively.
-
Nat Commun: What are the risk genes for skin cancer?
Time of Update: 2021-01-16
to track the lifetime risk of three types of skin cancer, the researchers also developed a second age-independent disease score, called DRSA.
by using incident cases, the researchers demonstrated that DRSA could be used in early detection programs to identify high-risk gradient individuals and predict when they might develop skin cancer.
-
Nat Commun: Wuhan University and other multi-unit cooperation! Zhongbo/Lindandan/Yuan reveals new potential therapeutic targets for non-small cell lung cancer
Time of Update: 2021-01-15
CCL7 showed high expression in NSCLC tumor tissue and was positively related to the immersion of cDC1 in TME and the overall survival of NSCLC patients.
-
Technology: Pioneering new technologies for exhaling detection and exploring new opportunities for the diagnosis of infectious diseases and tumors
Time of Update: 2021-01-15
Look and hear, sincerely for the medical program. cases of patients being diagnosed with the disease through exhaling tests have been going on for decades, and clinical studies over the past few deca
-
Lancet oncol: ICON8 Test Objective remission rate of ovarian, fallopian tubes and peritanotic cancer after a new line of assisted chemotherapy with carptin-yew alcohol
Time of Update: 2021-01-15
RECIST and GCIG CA125 remission of endocyst ovarian cancer with new complementary chemotherapy cannot be used as predictive markers for individual patients to distinguish or benefit from DPS, but can be combined with the clinical characteristics of patients for tumor reduction.
-
Hepatology|。 Post-liver transplant results in liver cancer patients: Multi-center queue report in the United States
Time of Update: 2021-01-15
same time, the U.S. Organ Procurement and Transplant Network recently approved the priority of liver transplants for HCC patients who exceed Milan's standards and are demoted through local location therapy.
